Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. News
  7. Summary
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BeiGene : SVB Leerink Adjusts BeiGene's Price Target to $417 from $388, Keeps Outperform Rating

06/14/2021 | 10:01am EDT


ę MT Newswires 2021
All news about BEIGENE, LTD.
01:00aPRESS RELEASE : Novartis delivers solid Q3 results, with strong growth in Innovative Medic..
DJ
10/21INSIDER SELL : Beigene
MT
10/21BEIGENE : and Nanolek Announce Approval in Russia for BRUKINSA« (Zanubrutinib) for Treatme..
PU
10/21BEIGENE, LTD. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ..
AQ
10/21BEIGENE : Russia Approves BeiGene's Cancer Medicine for Treatment of Mantle Cell Lymphoma
MT
10/20BEIGENE : Brukinsa Gets Russian Approval to Treat Certain Patients With Mantle Cell Lympho..
MT
10/20BEIGENE : and Nanolek Announce Approval in Russia for BRUKINSA« (Zanubrutinib) for Treatme..
BU
10/20Beigene and Nanolek Announce Approval in Russia for Brukinsa? (Zanubrutinib) for Treatm..
CI
10/14BEIGENE : SVB Leerink Adjusts Price Target on BeiGene to $414 From $417, Maintains Outperf..
MT
10/14BeiGene, Ltd. Provides Contract Update with Celgene Logistics Sàrl
CI
More news
Analyst Recommendations on BEIGENE, LTD.
More recommendations
Financials (USD)
Sales 2021 1 246 M - -
Net income 2021 -1 167 M - -
Net cash 2021 3 810 M - -
P/E ratio 2021 -33,3x
Yield 2021 -
Capitalization 35 804 M 35 804 M -
EV / Sales 2021 25,7x
EV / Sales 2022 23,9x
Nbr of Employees 6 400
Free-Float 68,2%
Chart BEIGENE, LTD.
Duration : Period :
BeiGene, Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEIGENE, LTD.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 383,64 $
Average target price 433,38 $
Spread / Average Target 13,0%
EPS Revisions
Managers and Directors
John V. Oyler Chairman & Chief Executive Officer
Xiao Bin Wu President & Chief Operating Officer
Julia Wang Chief Financial & Accounting Officer
Jane E. Huang Chief Medical Officer-Hematology
Yong Ben Chief Medical Officer-Immuno & Oncology Department
Sector and Competitors
1st jan.Capi. (M$)
BEIGENE, LTD.48.47%36 160
GILEAD SCIENCES, INC.16.25%84 845
BIONTECH SE258.67%71 229
WUXI APPTEC CO., LTD.23.63%64 399
REGENERON PHARMACEUTICALS22.57%59 906
VERTEX PHARMACEUTICALS-22.12%47 992